Galenea license Organix 5-HT2C agonists

Galenea have licensed Organix’s 5-HT2C agonists for the treatment of obesity and other related disorders.

Resolor (Prucalopride) safe and effective in Severe Chronic Constipation

Data presented at the United European Gastroenterology Week show Movetis’ Prucalopride to demonstrate efficacy and safety in patients with chronic constipation.

Pfizer publish series of Alpha1A Adrenoceptor Partial Agonists

Pfizer have published a series of 2-Imidazole Alpha1A Adrenoceptor Partial Agonists

Merck publish series of Histamine H3 Receptor Inverse Agonists

Merck have publsihed a series of 2-[4-(Aminoalkoxy)phenyl]-4(3H)-quinazolinone Histamine H3 Receptor Inverse Agonists

Tranzyme release Phase IIb results with Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI)

Tranzyme Pharma have released positive Phase IIb results for its ghrelin agonist, TZP-101, in the management of postoperative ileus (POI).

CV Therapeutics initiate Phase I trial of CVT-3619

CV Therapeutics have initiated a Phase 1 trial of partial A1 adenosine receptor agonist CVT-3619

Wyeth publishes series of Neurotensin NTS1 Receptor Partial Agonists

Wyeth have published a series of Neurotensin NTS1 Receptor Partial Agonists

Recordati publish series of 5-HT1A Full Agonists

Redordati have published a series of 1,4-dioxane 5-HT1A Full Agonists that are structurally related to WB 4101

Roche/Memory Expand R3487/MEM 3454 Development Program

Memory and Roche have announced plans to expand their nicotinic alpha-7 receptor agonist  R3487/MEM 3454 agreement to include Phase II trials of the drug in cognitive impairment associated with schizophrenia

AstraZeneca and Targacept present Phase IIb data on AZD3480 in Alzheimers Disease

Data from a Phase IIb clinical trial of AZD3480 in Alzheimer’s Disease were found to be inconclusive. Primary outcome measures were not statistically significant for either donepezil or AZD3480, however improvements were shown on secondary outcome measures ADCS-CGIC and MMSE.